Table 3.
Features and outcomes of the patients stratified by presence/absence of lupus anticoagulant
| Variable | Reference range | Total patients (n = 192) |
Patients with positive lupus anticoagulant (n = 95) |
Patients with negative lupus anticoagulant (n = 97) |
p-value |
|---|---|---|---|---|---|
| Age (years) | 69.4 ± 14.5 | 73.0 ± 14.0 | 65.8 ± 14.1 | 0.0005 | |
| Males (%) | 58.3 | 63.2 | 53.6 | 0.1808 | |
| History of Diabetes (%) | 17.2 | 17.9 | 16.5 | 0.7976 | |
| History of Hypertension (%) | 45.3 | 47.4 | 43.3 | 0.5722 | |
| History of CVD (%) | 23.4 | 26.3 | 20.6 | 0.3527 | |
| History of Lung Disease (%) | 9.9 | 11.6 | 8.2 | 0.4408 | |
| BMI | 27.9 ± 4.8 | 28.7 ± 5.6 | 27.0 ± 3.7 | 0.0136 | |
| eGFR (ml/min) | > 90 | 71.3 ± 27.1 | 68.1 ± 28.5 | 74.4 ± 25.6 | 0.1096 |
| CRP (mg/L) | < 5 | 142.2 ± 118.0 | 151.6 ± 101.5 | 123.0 ± 101.7 | 0.0072 |
| D-dimer (ng/ml) | < 200 | 1762.2 ± 5189.6 | 1568.9 ± 3700.7 | 1950.3 ± 6332.7 | 0.4407 |
| High-sensitivity Troponin (pg/ml) | < 20 | 40.0 ± 88.3 | 50.1 ± 105.3 | 29.9 ± 66.5 | 0.0009 |
| Lupus anticoagulant (%) | Negative | 49.5 | 100 | 0 | 1.000 |
| Prothrombin time (s) | 9.9–12.9 | 13.6 ± 3.0 | 14.5 ± 3.7 | 12.8 ± 1.8 | < 0.0001 |
| Activated partial-thromboplastin time (s) | 25–45 | 32.0 ± 5.2 | 34.2 ± 5.7 | 29.9 ± 3.7 | < 0.0001 |
| SaO2 (%) | > 93 | 89.9 ± 7.4 | 89.6 ± 8.1 | 90.3 ± 6.7 | 0.5028 |
| Lactate dehydrogenase (U/L) | 125–300 | 371.7 ± 229.6 | 356.7 ± 166.6 | 386.4 ± 278.0 | 0.2752 |
| Therapeutic anticoagulation (%) | 49.00 | 53.7 | 44.3 | 0.1960 | |
| Non-survivors (%) | 32.3 | 34.7 | 29.9 | 0.4745 | |
| Non survivors and survivors who required mechanical ventilation (%) | 39.6 | 42.1 | 37.1 | 0.4806 |
CVD cardiovascular disease, BMI body mass index, CRP: eGFR estimated glomerular filtration rate, CRP C-reactive protein, SaO2 oxygen saturation